Molybdenum Shortage May Limit Nuclear Medicine Services

Newswise — Problems with the world production and supply of molybdenum are leading to shortages of radioisotopes for nuclear medicine imaging tests, according to an editorial in the journal Nuclear Medicine Communications, official journal of the British Nuclear Medicine Society (BNMS). The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry.

International co-operation is needed to meet the challenges of maintaining a stable, reliable supply of radioactive tracers for essential bone, heart, and other imaging studies, according to the article by Alan C. Perkins of University of Nottingham and Gill Vivian of Plymouth Hospitals NHS Trust.

Supply Problems Disrupt Nuclear Medicine Services

Over the years, production and distribution of molybdenum—used to produce radiopharmaceuticals containing technetium-99m, widely used in nuclear medicine—has been highly reliable. However, problems have arisen due to the age of the commercial reactors that make molybdenum. All but one of the six reactors worldwide are more than 40 years old.

In the last two years, shutdowns of reactors in Canada and the Netherlands have led to disruptions in the supply of molybdenum to hospital nuclear medicine departments in the United Kingdom, Europe, and North America. With supplies reduced to 30 percent of normal, departments have had to adapt to make the most effective and efficient use of their supplies.

Earlier this year, the Nuclear Energy Agency convened an international workshop of molybdenum producers and distributors, nuclear medicine societies (including the BNMS), and clinicians to discuss the problem. "In the foreseeable future there will be further disruptions in molybdenum supplies and the cost will increase significantly," workshop attendees agreed. At the same time, they pledged to address the problems through exchange of materials, information, and strategic support.

Call for International Co-operation to Address Shortage

However, many challenges will have to be met to ensure and maintain an adequate world supply of medical molybdenum. The small number of ageing reactors poses problems—new reactors require significant time and investment, and new technologies for molybdenum supply are limited. Attention is needed to the complex supply chain involved in producing and distributing a decaying radioactive product.

Co-operative efforts will also be needed to address security issues related to the proliferation of nuclear material. Meanwhile, nuclear medicine departments will have to devise ways of making the best use of limited supplies, including efficiencies in patient scheduling and radiopharmaceutical use and new means of achieving results while using lower doses of radioactivity.

Currently, neither the United Kingdom nor the United States has a facility for producing medical molybdenum. The current interest in sustainable "green" energy may drive a "nuclear renaissance," which the authors hope will include provisions for the manufacture of radiopharmaceuticals.

"The medical use of radionuclides is probably the single most beneficial application of atomic and nuclear sciences to mankind," Drs. Perkins and Vivian conclude. The BNMS will play a central role in minimizing the impact of the molybdenum shortage on patient services while advocating investment in alternative means of meeting the critical demand for medical radioisotopes.

About Nuclear Medicine Communications

Nuclear Medicine Communications (http://www.nuclearmedicinecomm.com) is a monthly journal publishing research and clinical work in all areas of nuclear medicine for an international readership. In addition to refereed papers, the journal features frankly written editorials, topical reviews, book reviews, and reporting of international conferences. Nuclear Medicine Communications is official journal of the British Nuclear Medicine Society (http://www.bnms.org.uk).

About Lippincott Williams & Wilkins

Lippincott Williams & Wilkins (LWW) is a leading international publisher for healthcare professionals and students with nearly 300 periodicals and 1,500 books in more than 100 disciplines publishing under the LWW brand, as well as content-based sites and online corporate and customer services. LWW is part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry.

Wolters Kluwer Health is a division of Wolters Kluwer, a leading global information services and publishing company. The company provides products and services for professionals in the health, tax, accounting, corporate, financial services, legal, and regulatory sectors. Wolters Kluwer had 2008 annual revenues of €3.4 billion ($4.9 billion), employs approximately 20,000 people worldwide, and maintains operations in over 35 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Amsterdam, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Visit www.wolterskluwer.com for information about our market positions, customers, brands, and organization.